Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Corticosteroids are widely used in IgA nephropathy (IgAN) for their renoprotective effects, yet concerns remain about their long-term safety. The influence of baseline characteristics on steroid-related adverse events is unclear, and it is uncertain whether delaying progression to end-stage kidney disease reduces systemic complications. Two recent nationwide Japanese cohort studies (JNR-IgAN 2019 and J-IGACS 2023) showed slower renal decline with corticosteroid use. This study aimed to evaluate the association between corticosteroid therapy and systemic adverse outcomes in patients with IgAN.
We conducted a post hoc analysis using two datasets derived from JNR-IgAN 2019 (n=1065) and J-IGACS 2023 (n=941). Patients in each cohort were stratified according to corticosteroid use within the first year of follow-up: corticosteroid users (CS) and non-users (non-CS), with the latter serving as the reference group. Overlap weighting was applied to each dataset to adjust for baseline imbalances. The primary outcome was the total number of adverse events, including infections, new-onset diabetes mellitus, cerebrovascular, cardiovascular, and other systemic complications. Secondary outcomes comprised individual components of the primary outcome. Incidence risk ratios (IRRs) were estimated using negative binomial regression for each cohort and subsequently pooled. Key baseline variables were identified via multivariable analysis and their associations with corticosteroid-related IRRs were explored using restricted cubic spline modeling.
The number of primary outcome events was 95 in JNR-IgAN 2019 and 103 in J-IGACS 2023. The pooled IRR for the primary outcome (CS vs. non-CS) was 3.25 (95% CI: 0.68–15.58). In both the JNR-IgAN 2019 and J-IGACS 2023 cohorts, IRRs increased steeply and exhibited a non-linear association with advancing age. Regarding secondary outcomes, corticosteroid use was associated with elevated risks of infection (pooled IRR: 6.99, 95% CI: 0.39–126.1), new-onset diabetes mellitus (pooled IRR: 26.7, 95% CI: 1.36–526.3), and composite events including death, malignancy, and orthopedic disorders (pooled IRR: 8.01, 95% CI: 0.99–64.7). Conversely, the risk of cerebrovascular, cardiovascular, and vascular events was significantly lower in corticosteroid-treated patients (pooled IRR: 0.02, 95% CI: 0.00–0.26).
This study informs clinical practice by emphasizing the need for individualized corticosteroid use in IgAN. Although corticosteroids may offer renal benefits, their association with increased risks of infection, new-onset diabetes, and other systemic complications—particularly in older patients—calls for careful patient selection and monitoring. Age-dependent escalation of adverse events suggests that immunosuppressive strategies should be tailored based on patient vulnerability, not applied uniformly. The unexpected reduction in vascular-related events warrants further investigation and may help refine future risk-benefit assessments.
